Kingkan Bunluepeuch

Dr. Kingkan Bunluepeuch


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Heliyon
Verified
Journal Article
Open access
KEKomgrit Eawsakul
Komgrit Eawsakul
PPPharkphoom Panichayupakaranant
Pharkphoom Panichayupakaranant
TOTassanee Ongtanasup
Tassanee Ongtanasup
Sakan WarinhomhounSakan Warinhomhoun
Sakan Warinhomhoun
KNKunwadee Noonong
Kunwadee Noonong
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
The number of patients with type 2 diabetes mellitus (T2DM) has increased worldwide. Although an instant cure was achieved with the standard treatment acabose, unsatisfactory symptoms associated with cardiovascular disease after acabose administration have been reported. Therefore, it is important to explore new treatments. A Thai folk recipe has long been used for T2DM treatment, and it effectively decreases blood glucose. However, the mechanism of this recipe has never been proven. Therefore, the potential anti-T2DM effect of this recipe, which is used in Thai hospitals, was determined to involve alpha-glucosidase (AG) inhibition with a half maximal inhibitory concentration (IC50). In vitro experiments showed that crude Cinnamomum verum extract (IC50 = 0.35 ± 0.12 mg/mL) offered excellent inhibitory activity, followed by extracts from Tinospora crispa (IC50 = 0.69 ± 0.39 mg/mL), Stephania suberosa (IC50 = 1.50 ± 0.17 mg/mL), Andrographis paniculate (IC50 = 1.78 ± 0.35 mg/mL), and Thunbergia laurifolia (IC50 = 4.66 ± 0.27 mg/mL). However, the potencies of these extracts were lower than that of acabose (IC50 = 0.55 ± 0.11 mg/mL). Therefore, this study investigated and developed a formulation of this recipe using computational docking. Among 61 compounds, 7 effectively inhibited AG, including chlorogenic acid (IC50 = 819.07 pM) through 5 hydrogen bonds (HBs) and 2 hydrophobic interactions (HIs); β-sitosterol (IC50 = 4.46 nM, 6 HIs); ergosterol peroxide (IC50 = 4.18 nM, 6 HIs); borapetoside D (IC50 = 508.63 pM, 7 HBs and 2 HIs); borapetoside A (IC50 = 1.09 nM, 2 HBs and 2 His), stephasubimine (IC50 = 285.37 pM, 6 HIs); and stephasubine (IC50 = 1.09 nM, 3 HBs and 4 HIs). These compounds bind with high affinity to different binding pockets, leading to additive effects. Moreover, the pharmacokinetics of six of these seven compounds (except ergosterol peroxide) showed poor absorption in the gastrointestinal tract, which would allow for competitive binding to AG in the small intestine. These results indicate that the development of these 6 compounds into oral antidiabetic agents is promising.

30 January 2023 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
KEKomgrit Eawsakul
Komgrit Eawsakul
TOTassanee Ongtanasup
Tassanee Ongtanasup
NNNgamrayu Ngamdokmai
Ngamrayu Ngamdokmai
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Introduction: Bioactive compounds from traditional medicines are good alternatives to standard diabetes therapies and may lead to new therapeutic discoveries. The stems of Bauhinia strychnifolia Craib. (BC) have a possible antihyperglycemic effect; However, the extraction of astilbin from BC has never been recorded in alpha-glucosidase inhibitory activities. Methods: Using liquid chromatography–mass spectrometry (LC–MS/MS), 32 compounds were detected in the BC extract. The screening was based on peak area. Seven compounds found. PASS recognized all seven compounds as potential alpha-glucosidase (AG) inhibitors. Astilbin and quercetin 3-rhamnoside were the most likely inhibitors of AG. Arguslab, AutoDock, and AutoDock Vina investigated the binding of the two compounds and AG. The binding stability was confirmed by molecular dynamics (MD). In addition, the optimum solvent extraction was studied via CosmoQuick, and extracts were examined with 1H-NMR prior to testing with AG. Results: All three software programs demonstrated that both compounds inhibit AG more effectively than acarbose. According to the sigma profile, THF is recommended for astilbin extraction. The BC extract with THF showed outstanding AG inhibitory action with an IC50 of 158 ± 1.30 µg mL-1, which was much lower than that of the positive control acarbose (IC50 = 190 ± 6.97 µg mL-1). In addition, astilbin from BC was found to inhibit AG strongly, IC50 = 22.51 ± 0.70 µg mL-1 through the extraction method of large-scale astilbin with THF has the best extraction capacity compared to other solvents, hence the initial stage of extraction employs THF to extract and precipitate them with ethyl acetate and water. Conclusion: In silico and in vitro studies reveal that astilbin inhibits AG and is superior to acarbose, validating its promise as an AG inhibitor. Overall, astilbin was the most bioactive component of BC for antidiabetic action.

5 September 2022 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
KNKunwadee Noonong
Kunwadee Noonong
KPKanta Pranweerapaiboon
Kanta Pranweerapaiboon
KCKulathida Chaithirayanon
Kulathida Chaithirayanon
KSKantamat Surayarn
Kantamat Surayarn
PDPhicharinee Ditracha
Phicharinee Ditracha
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Background: Lysiphyllum strychnifolium (Craib) A. Schmitz, a traditional Thai medicinal plant, is mainly composed of polyphenols and flavonoids and exhibits several pharmacological activities, including antioxidant, anticancer, antimicrobial, and antidiabetic activities. However, the mechanism by which pure compounds from L. strychnifolium inhibit glucose catalysis in the small intestine and their effect on the glucose transporter remain unknown. Methods: The objectives of this research were to examine the effect of 3,5,7-trihydroxychromone-3-O-𝛼-L-rhamnopyranoside (compound 1) and 3,5,7,3’,5’-pentahydroxy-flavanonol-3-O-𝛼-L-rhamnopyranoside (compound 2) on the inhibition of α-amylase and α-glucosidase, as well as glucose transporters, such as sodium-glucose cotransporter 1 (SGLT1), glucose transporter 2 (GLUT2), and glucose transporter 5 (GLUT5), using Caco-2 cells as a model of human intestinal epithelial cells. Additionally, the binding affinity and interaction patterns of compounds against two receptor proteins (SGLT1 and GLUT2) were determined for the first time utilizing a molecular docking approach. Results: In the α-amylase inhibition assay, a concentration-dependent inhibitory response was observed against the enzyme. The results indicated that compound 1 inhibited α-amylase activity in a manner similar to that of acarbose (which exhibit IC50 values of 3.32 ± 0.30 µg/mL and 2.86 ± 0.10 µg/mL, respectively) in addition to a moderate inhibitory effect for compound 2 (IC50 = 10.15 ± 0.53 µg/mL). Interestingly, compounds 1 and 2 significantly inhibited α-glucosidase and exhibited better inhibition than that of acarbose, with IC50 values of 5.35 ± 1.66 µg/mL, 510.15 ± 1.46 µg/mL, and 736.93 ± 7.02 µg/mL, respectively. Additionally, α-glucosidase activity in the supernatant of the Caco-2 cell monolayer was observed. In comparison to acarbose, compounds 1 and 2 inhibited α-glucosidase activity more effectively in Caco-2 cells without cytotoxicity at a concentration of 62.5 µg/mL. Furthermore, the glucose uptake pathways mediated by SGLT1, GLUT2, and GLUT5- were downregulated in Caco-2 cells treated with compounds 1 and 2. Additionally, molecular modeling studies revealed that compounds 1 and 2 presented high binding activity with SGLT1 and GLUT2. Conclusion: In summary, our present study was the first to perform molecular docking with compounds present in L. strychnifolium extracts. Our findings indicated that compounds 1 and 2 reduced glucose uptake in Caco-2 cells by decreasing the expression of glucose transporter genes and inhibiting the binding sites of SGLT1 and GLUT2. Therefore, compounds 1 and 2 may be used as functional foods in dietary therapy for postprandial hyperglycemia modulation of type 2 diabetes.

1 January 2024 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
Komgrit EawsakulKomgrit Eawsakul
Komgrit Eawsakul
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Compared with the use of a single herb alone, herb combinations can significantly increase their effectiveness in treating various diseases. The objective of this research was to determine the appropriate proportions of Garcinia mangostana (GM), Curcuma comosa (CC), and Acanthus ebracteatus (AE) to enhance their antioxidant and anti‐inflammatory properties. The study employed computer modeling (in silico) and laboratory testing (in vitro). The optimal levels of phenolic and flavonoid compounds were achieved with a ratio of 15 parts GM, 5 parts CC, and 10 parts AE. In contrast, the 10 : 15 : 5 ratio resulted in the highest antioxidant activity, reducing DPPH radicals by 80.33% and ABTS radicals by 92.20%. The ratio had a synergistic effect and was within the safe range, ranging from 82.97 to 147.04 µg/mL. The ratio of 5 : 10 : 15 had the greatest anti‐inflammatory effects, with an exceptional activity level of 98.86%. It effectively suppressed 23 genes or proteins, including the prominent NFE2L2 gene, and had a synergistic effect. This combination effectively inhibits inflammation (IC50: 12.05 µg/mL) and is safe for macrophages at concentrations up to 50 µg/mL. These findings emphasize the potential of these herbal mixtures for antioxidant and anti‐inflammatory applications.

10 July 2025 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
KEKomgrit Eawsakul
Komgrit Eawsakul
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
SWSueptrakool Wisessombat
Sueptrakool Wisessombat
Acne vulgaris (AV) is a common, long-lasting skin condition characterized by inflammation that is frequently linked to the bacteria Cutibacterium acnes (C. acnes) and Staphylococcus spp. Conventional medicines face difficulties, such as bacterial resistance, in treating acne vulgaris, highlighting the need for new treatment approaches. In this study, we investigated the antibacterial activity of three medicinal plants, Garcinia mangostana (GM), Curcuma comosa (CC), and Acanthus ebracteatus (AE), which are traditionally used to treat different illnesses because of their antibacterial, antioxidant, and anti-inflammatory properties. We utilized a mix of in silico, in vitro, and molecular dynamics (MD) techniques to assess their abilities to treat skin breakouts. We found that the active ingredients in these herbs significantly interact with several bacterial and human inflammatory proteins. Specifically, the herbal components strongly bind to the bacterial enzyme topoisomerase II alpha (TOP2α), which is fundamental for bacterial DNA replication and repair, as well as to human nuclear factor kappa B subunit 1 (NFκB1), which is a vital marker of inflammation. The findings from this study suggest that this combination treatment offers two advantages, preventing bacterial growth and reducing inflammation, making it a promising choice for skin breakouts. In addition, this combination was not toxic to fibroblasts, supporting its capacity as a safe skin treatment. Interestingly, at a 15:5:10 GM:CC:AE ratio, this combination treatment displayed high selectivity indices (SIs) against Staphylococcus epidermidis (26.87) and C. acnes (4.99), indicating its strong therapeutic potential without side effects. In conclusion, our study highlights that this combination is a novel, effective, and safe choice for controlling acne vulgaris, especially because of its ability to inhibit TOP2α and regulate NFκB1.

1 January 2026 in Scientifica
Verified
Journal Article
Open access
KLKunwadee Lao-On
Kunwadee Lao-On
ULUdom Lao-On
Udom Lao-On
ASAnunya Suksanga
Anunya Suksanga
RKRungruedee Kimseng
Rungruedee Kimseng
Rahni HossainRahni Hossain
Rahni Hossain
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Diabetes mellitus, a condition characterized by hyperglycemia, poses significant global health concern. Despite the availability of several antidiabetic drugs, the search for new therapeutic agents with fewer side effects and better efficacy continues. Phanera strychnifolia (Craib) K. W. Jiang, S. R. Gu, & T. Y. Tu, a medicinal plant traditionally used in Southeast Asia, has gained attention for its bioactive components. Two major compounds isolated, namely, 3,5,7‐trihydroxychromone‐3‐O‐α‐L‐rhamnopyranoside and 3,5,7,3′,5′‐pentahydroxy‐flavanonol‐3‐O‐α‐L‐rhamnopyranoside, have shown promise as antihyperglycemic agents in human intestinal epithelial Caco‐2 cells. It had been demonstrating antidiabetic and antioxidant activities of its aqueous extract in both in vivo and in vitro studies with limited information regarding their antihyperglycemic effect on insulin secretion and glucose transporter expression. Therefore, this study aims to evaluate the impact of P. strychnifolia extracts on blood glucose levels in diabetic rats and to investigate the expression of glucose transporter proteins (GLUT2 and GLUT4) and insulin production in relevant tissues to elucidate the mechanisms of improved glucose uptake and utilization. The antidiabetic effect of P. strychnifolia was determined by histological staining and immunocytochemical localization of insulin, GLUT2, and GLUT4 in pancreatic islets and the heart. Additionally, toxicity assessment was conducted over a 63‐day administration by observing biochemical parameters and histological changes. P. strychnifolia demonstrates nontoxic characteristics, as evidenced by the absence of mortality and clinical toxicity signs at the 400 mg/kg dose after 63 days of treatment. In diabetic rats, administration of 100 and 200 mg/kg of P. strychnifolia for 14 days significantly reduced blood glucose levels by approximately 45.65% and 41.01%, respectively, compared to the diabetic control group. Both doses effectively reduced lipid droplets in the liver, indicating decreased tissue injury. P. strychnifolia demonstrates significant antihyperglycemic activity and beneficial effects on insulin and glucose transporter protein expression in diabetic rats, with no observed toxicity. These findings suggest its potential as a therapeutic agent for diabetes management.